検索に戻る
案件記録

IN-SILICO CARDIAC DISEASE DATABASE UTILIZATION METHOD, IN-SILICO CARDIAC DISEASE DATABASE UTILIZATION PROGRAM AND INFORMATION PROCESSING DEVICE

発明審査中
10請求項 · 3 独立
§ Ⅰ

案件概要

出願人

UT-Heart Inc.

発明者

Toshiaki HISADA; Seiryo SUGIURA; Takumi WASHIO; Jun-ichi OKADA; Katsuhito FUJIU

IPC分類

G16H 50/70A61B 8/A61B 8/8G16H 50/20

CPC分類

G16H50/70G16H50/20A61B8/883A61B8/5284

An information processing technology capable of increasing prediction accuracy of causing cardiac diseases, performing appropriate therapy and increasing efficiency of drug development is constructed by utilizing “in-silico cardiac disease database.” An electrocardiogram and the like obtained from “in-silico cardiac disease database” which is the database storing a simulation result of a cardiac model of virtual disease where various factor related to cardiac disease are changed are inputted to a classifier for performing an automatic diagnosis of the cardiac disease, and an influencing factor associated with the cardiac disease is identified as a biomarker by comparing distributions of a variation amount of a factor between a positive group and a negative group. In addition, precise diagnosis of an individual is easily performed by identifying the cardiac model having the electrocardiogram and the like appropriate to the actual electrocardiogram and the like of the individual in the in-silico cardiac disease database. Furthermore, the process of drug development is efficiently performed by extracting a group having a predetermined feature from the in-silico cardiac disease database and simply evaluating an effect of an administration of a medical agent.

原文(中国語)

An information processing technology capable of increasing prediction accuracy of causing cardiac diseases, performing appropriate therapy and increasing efficiency of drug development is constructed by utilizing “in-silico cardiac disease database.” An electrocardiogram and the like obtained from “in-silico cardiac disease database” which is the database storing a simulation result of a cardiac model of virtual disease where various factor related to cardiac disease are changed are inputted to a classifier for performing an automatic diagnosis of the cardiac disease, and an influencing factor associated with the cardiac disease is identified as a biomarker by comparing distributions of a variation amount of a factor between a positive group and a negative group. In addition, precise diagnosis of an individual is easily performed by identifying the cardiac model having the electrocardiogram and the like appropriate to the actual electrocardiogram and the like of the individual in the in-silico cardiac disease database. Furthermore, the process of drug development is efficiently performed by extracting a group having a predetermined feature from the in-silico cardiac disease database and simply evaluating an effect of an administration of a medical agent.

外部リソース